Literature DB >> 17230537

Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.

Eric L Logigian1, Emma Ciafaloni, L Christine Quinn, Nuran Dilek, Shree Pandya, Richard T Moxley, Charles A Thornton.   

Abstract

To characterize and compare electrical myotonia in myotonic dystrophy type 1 (DM1) and type 2 (DM2), 16 patients with genetically confirmed DM1 and 17 patients with DM2 underwent standardized concentric needle electromyography of deltoid, biceps, extensor digitorum communis, first dorsal interosseous, tensor fascia lata (TFL), vastus lateralis (VL), tibialis anterior, and thoracic paraspinal muscles. Eight needle insertions per muscle were made by electromyographers blinded to DM type who recorded the presence and type of myotonia (e.g., classic waxing-waning or less specific waning discharges). Manual muscle testing was performed by a physical therapist. Overall, myotonia was more elicitable in DM1 than DM2; only in VL and TFL was myotonia more elicitable in DM2 than DM1. The major type of myotonia was waxing-waning in DM1, and waning in DM2. Four DM2 (24%), but no DM1 patients had only waning myotonia. In the arms, myotonia was distally predominant in both DM1 and DM2. In the legs, it was distally predominant in DM1, but both proximal and distal in DM2. The severity of myotonia was positively correlated with muscle weakness and with the presence of waxing and waning discharges in DM1, but with neither in DM2. Thus, myotonia is qualitatively and quantitatively different in DM1 than DM2. Except for proximal leg muscles, myotonia is more evocable in DM1 than DM2. It tends to be waxing-waning in DM1 but waning in DM2, thus making electrodiagnosis of DM2 more challenging. Its severity correlates with muscle weakness and the presence of waxing-waning discharges in DM1 but not DM2.

Entities:  

Mesh:

Year:  2007        PMID: 17230537     DOI: 10.1002/mus.20722

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

Review 1.  Positive muscle phenomena--diagnosis, pathogenesis and associated disorders.

Authors:  Hans G Kortman; Jan H Veldink; Gea Drost
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

2.  Techniques and applications of EMG: measuring motor units from structure to function.

Authors:  Rachel C Thornton; Andrew W Michell
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

3.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

4.  Electromechanical delays during a fatiguing exercise and recovery in patients with myotonic dystrophy type 1.

Authors:  Fabio Esposito; Emiliano Cè; Susanna Rampichini; Elena Monti; Eloisa Limonta; Barbara Fossati; Giovanni Meola
Journal:  Eur J Appl Physiol       Date:  2017-02-14       Impact factor: 3.078

Review 5.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 6.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

Review 7.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

8.  HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1.

Authors:  Debra A O'Leary; Leonardo Vargas; Orzala Sharif; Michael E Garcia; Yury J Sigal; Siu-Kei Chow; Christian Schmedt; Jeremy S Caldwell; Achim Brinker; Ingo H Engels
Journal:  Curr Chem Genomics       Date:  2010-03-19

9.  Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1.

Authors:  Eric L Logigian; Paul Twydell; Nuran Dilek; William B Martens; Chris Quinn; Allen W Wiegner; Chad R Heatwole; Charles A Thornton; Richard T Moxley
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

Review 10.  Myotonic dystrophy: therapeutic strategies for the future.

Authors:  Thurman M Wheeler
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.